Explore BioCardia's Q2 2025 insights, highlighting regulatory milestones, CardiAMP trial progress, upcoming financing & partnerships.

Q4 2025 Management View CEO William L. Ballhaus opened the call emphasizing, "We delivered very strong results in Q4 that were once again in line with or ahead of our expectations, resulting in solid ...

Repay Holdings Corporation ( NASDAQ: RPAY) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET John Andrew Morris - CEO, Co-Founder & Director Stewart Joseph Grisante - Head of Investor ...